FDA Clearance Tracker · P030017-S358
mySCS GO Therapy Controller App
Last checked: Nov 20, 2026Latest source record: Apr 4, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Apr 4, 2024
Approved
Time to decision
463 days
Received Dec 28, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P030017-S358
- Device name
- mySCS GO Therapy Controller App
- Applicant
- Boston Scientific Corp
- Applicant location
- Valencia, CA
- Received
- Dec 28, 2022
- Decided
- Apr 4, 2024
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P030017
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for a mobile application referred to as the mySCSTM GO Therapy Controller App. The mySCSTM GO Therapy Controller App will be used on an off-the-shelf mobile phone and functions as an alternate to the current FreelinkTM Remote Control (RC) to control the WaveWriter Alpha IPG and External Trial Stimulator (ETS) Systems (P030017/S338).
Source documents
Other decisions for Boston Scientific Corp
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P130030 · Decided Mar 10, 2026 · 4,453 days after receipt
Device type: STENT, CORONARY (MAF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.